Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Fouad T. Chebib, Ronald D. Perrone, Arlene B. Chapman, et al.
Journal of the American Society of Nephrology (2018) Vol. 29, Iss. 10, pp. 2458-2470
Open Access | Times Cited: 208

Showing 1-25 of 208 citing articles:

Polycystic kidney disease
Carsten Bergmann, Lisa M. Guay‐Woodford, Peter C. Harris, et al.
Nature Reviews Disease Primers (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 592
Autosomal dominant polycystic kidney disease
Émilie Cornec-Le Gall, Ahsan Alam, Ronald D. Perrone
The Lancet (2019) Vol. 393, Iss. 10174, pp. 919-935
Closed Access | Times Cited: 453
Ciliopathies and the Kidney: A Review
Dominique J. Mcconnachie, Jennifer L. Stow, Andrew Mallett
American Journal of Kidney Diseases (2020) Vol. 77, Iss. 3, pp. 410-419
Open Access | Times Cited: 167
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary
Vicente E. Torres, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. 234-254
Open Access | Times Cited: 5
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 4
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
Roman‐Ulrich Müller, A. Lianne Messchendorp, Henrik Birn, et al.
Nephrology Dialysis Transplantation (2021) Vol. 37, Iss. 5, pp. 825-839
Open Access | Times Cited: 96
Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease
Yi Lu, Yongzhan Sun, Zhiheng Liu, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 554
Closed Access | Times Cited: 86
Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy
Fouad T. Chebib, Vicente E. Torres
American Journal of Kidney Diseases (2021) Vol. 78, Iss. 2, pp. 282-292
Closed Access | Times Cited: 67
Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)
Ronald D. Perrone, Kaleab Z. Abebe, Terry Watnick, et al.
Kidney International (2021) Vol. 100, Iss. 3, pp. 684-696
Open Access | Times Cited: 64
Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
Peiyang Cao, Qian Wang, Yan Wang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access | Times Cited: 1
Autosomal Dominant Polycystic Kidney Disease
Fouad T. Chebib, Christian Hanna, Peter C. Harris, et al.
JAMA (2025)
Closed Access | Times Cited: 1
Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease
Jonathan Wang, Deborah D. Chin, Christopher Poon, et al.
Journal of Controlled Release (2020) Vol. 329, pp. 1198-1209
Open Access | Times Cited: 68
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD
Sravanthi Lavu, Lisa E. Vaughan, Sarah R. Senum, et al.
JCI Insight (2020) Vol. 5, Iss. 15
Open Access | Times Cited: 62
The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles
Yi Huang, Kairui Jiang, Xuting Zhang, et al.
Bioengineering & Translational Medicine (2020) Vol. 5, Iss. 3
Open Access | Times Cited: 55
Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases
Emma T. B. Olesen, Robert A. Fenton
Nature Reviews Nephrology (2021) Vol. 17, Iss. 11, pp. 765-781
Closed Access | Times Cited: 54
Genetic Etiologies for Chronic Kidney Disease Revealed through Next-Generation Renal Gene Panel
Anthony J. Bleyer, Maggie Westemeyer, Jing Xie, et al.
American Journal of Nephrology (2022) Vol. 53, Iss. 4, pp. 297-306
Open Access | Times Cited: 34
Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD
Bart J. Kramers, Iris W. Koorevaar, Maatje D.A. van Gastel, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 4, pp. 507-517
Open Access | Times Cited: 28
Biomarkers of Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Ahmad Ghanem, Abdul Hamid Borghol, Fadi George Munairdjy Debeh, et al.
Kidney International Reports (2024) Vol. 9, Iss. 10, pp. 2860-2882
Open Access | Times Cited: 7
Renal ciliopathies
Laura A. Devlin, John A. Sayer
Current Opinion in Genetics & Development (2019) Vol. 56, pp. 49-60
Closed Access | Times Cited: 50
Vasopressin–aquaporin-2 pathway: recent advances in understanding water balance disorders
Marianna Ranieri, Annarita Di Mise, Grazia Tamma, et al.
F1000Research (2019) Vol. 8, pp. 149-149
Open Access | Times Cited: 43
Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review
Niloofar Nobakht, Ramy M. Hanna, Maha Al-Baghdadi, et al.
Kidney Medicine (2020) Vol. 2, Iss. 2, pp. 196-208
Open Access | Times Cited: 41
Therapeutic advances in ADPKD: the future awaits
Ivana Capuano, Pasquale Buonanno, Eleonora Riccio, et al.
Journal of Nephrology (2021) Vol. 35, Iss. 2, pp. 397-415
Closed Access | Times Cited: 34
Atypical Polycystic Kidney Disease as defined by Imaging
Ioan-Andrei Iliuta, Aung Zaw Win, Matthew B. Lanktree, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 13
Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial
Eiji Higashihara, Miyuki Matsukawa, Huan Jiang
Clinical and Experimental Nephrology (2025)
Open Access
Risk-directed management of chronic kidney disease
Matthew F. Blum, Brendon L. Neuen, Morgan E. Grams
Nature Reviews Nephrology (2025)
Closed Access
Page 1 - Next Page

Scroll to top